Albany, US – DelveInsight has launched a new report on Short Bowel Syndrome Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s “Short Bowel Syndrome – Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Short Bowel Syndrome, historical and forecasted epidemiology as well as the Short Bowel Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of the key facts of the Report:
- The prevalence of Short Bowel Syndrome in Germany is 34 per million inhabitants.
- The most common cause of Short Bowel Syndrome in infants and babies is necrotizing enterocolitis (NEC) which accounts for up to 40% of SBS patients.
- Short Bowel Syndrome affected not more than 0.35 in 10,000 people in the European Union (EU).
- Several conditions requiring intestinal resection lead to Short Bowel Syndrome. These conditions include postoperative (25%), irradiation/cancer (24%), mesenteric vascular disease (22%), Crohn’s disease (16%), and other benign causes (13%).
Key benefits of the Report
1. Short Bowel Syndrome market report covers a descriptive overview and comprehensive insight of the Short Bowel Syndrome epidemiology and Short Bowel Syndrome market in the 7 MM (United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Short Bowel Syndrome market report provides insights on the current and emerging therapies.
3. Short Bowel Syndrome market report offers a global historical and forecasted market covering drug outreach in 7 MM.
4. Short Bowel Syndrome market report provides an edge that will help in developing business strategies by understanding trends shaping and driving the Short Bowel Syndrome market.
Request for Sample Pages: https://www.delveinsight.com/sample-request/short-bowel-syndrome-market
“According to DelveInsight, women are more likely to suffer from Short Bowel Syndrome as compared to men.”
Short bowel syndrome (SBS) is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine.
SBS is generally broken down into individuals in whom the disorder is acquired during life and newborns in which the disorder is present at birth (congenital). Acquired short bowel syndrome is more common than the congenital form of the disorder.
The specific symptoms and severity of SBS vary from one person to another. Diarrhea is common, often severe and can cause dehydration, which can even be life-threatening. SBS can lead to malnutrition, unintended weight loss, and additional symptoms may be due to the loss of essential vitamins and minerals.
SBS is most commonly associated with surgical removal (resection) of half or more of the small intestine. Such surgery is performed to treat intestinal diseases such as Crohn’s disease, injury or trauma to the small bowel, or congenital birth defects.
“DelveInsight estimates an increase in Short bowel syndrome Market Size during the study period, 2017 – 2030.”
Some of the key companies working on Short bowel syndrome are:
- Zealand Pharma
- Therachon AG
And Many Others.
The launch of the emerging therapies is expected to significantly impact the Short bowel syndrome treatment scenario in the upcoming years:-
Drugs Covered:
- Glepaglutide
- Apraglutide
And Many Others.
Request a Free Sample Report @ https://www.delveinsight.com/sample-request/short-bowel-syndrome-market
Table of Contents:
1. Report Introduction
2. Short Bowel Syndrome: Market Overview at a Glance
2.1. Global Market Size of Short Bowel Syndrome in 2017
2.2. Global Market Size of Short Bowel Syndrome in 2030
3. Disease Background and Overview: Short Bowel Syndrome
3.1. Introduction
3.2. Causes
3.3. Pathophysiology
3.4. Symptoms
3.5. Risk Factor
3.6. Diagnosis
4. Epidemiology and Patient Population
4.1. Assumptions and Caveats
4.2. Short Bowel Syndrome Geography Wise Prevalent Cases
4.2.1. 7MM Prevalent Cases of Short Bowel Syndrome in 2017
4.2.2. 7MM Prevalent Cases of Short Bowel Syndrome in 2030
4.3. United States
4.3.1. Prevalent Cases of Short Bowel Syndrome in the United States (2017–2030)
4.3.2. Diagnosed and Treatable Cases of Short Bowel Syndrome in the United States (2017–2030)
4.4. EU-5
4.4.1. Germany
4.4.1.1. Prevalent Cases of Short Bowel Syndrome in Germany (2017–2030)
4.4.1.2. Diagnosed and Treatable Cases of Short Bowel Syndrome in Germany (2017–2030)
4.4.2. France
4.4.2.1. Prevalent Cases of Short Bowel Syndrome in France (2017–2030)
4.4.2.2. Diagnosed and Treatable Cases of Short Bowel Syndrome in France (2017–2030)
4.4.3. Italy
4.4.3.1. Prevalent Cases of Short Bowel Syndrome in Italy (2017–2030)
4.4.3.2. Diagnosed and Treatable Cases of Short Bowel Syndrome in Italy (2017–2030)
4.4.4. Spain
4.4.4.1. Prevalent Cases of Short Bowel Syndrome in Spain (2017–2030)
4.4.4.2. Diagnosed and Treatable Cases of Short Bowel Syndrome in Spain (2017–2030)
4.4.5. United Kingdom
4.4.5.1. Prevalent Cases of Short Bowel Syndrome in the UK (2017–2030)
4.4.5.2. Diagnosed and Treatable Cases of Short Bowel Syndrome in the UK (2017–2030)
4.5. Japan
4.5.1. Prevalent Cases of Short Bowel Syndrome in Japan (2017–2030)
4.5.2. Diagnosed and Treatable Cases of Short Bowel Syndrome in Japan (2017–2030)
5. Treatment Practices
5.1. Treatment Algorithm
5.2. Treatment Guidelines
5.2.1. European Society for Clinical Nutrition and Metabolism (ESPEN): Recommendations
6. Marketed Products
6.1. Gattex (teduglutide): NPS Pharmaceuticals (Acquired by Shire Plc.)
6.1.1. Drug Description
6.1.2. Mechanism of Action
6.1.3. Regulatory Milestones
6.1.4. Advantages & Disadvantages
6.1.5. Safety and Efficacy
6.1.6. Product Profile
7. Key Emerging Therapies
7.1. Key Cross Competition
7.2. Glepaglutide: Zealand Pharma A/S
7.2.1. Regulatory Milestones
7.2.2. Clinical Development
7.2.3. Product Profile
7.2.4. Clinical Pipeline Activity
7.2.5. Ongoing Trials Information
7.2.6. Clinical Trial by Phase
7.3. Apraglutide: Therachon AG
7.3.1. Regulatory Milestones
7.3.2. Clinical Development
7.3.3. Product Profile
7.3.4. Clinical Pipeline Activity
7.3.5. Ongoing Trials Information
7.3.6. Clinical Trial by Phase
To be continued in the report…
8. Short Bowel Syndrome Market Size
8.1. Key Findings
8.2. Total 7MM Short Bowel Syndrome Market Analysis
8.3. Overview of Total Short Bowel Syndrome Market
8.4. 7MM Short Bowel Syndrome: Country-Wise Market Analysis
8.4.1. United States
8.4.1.1. Total Market Size of Short Bowel Syndrome
8.4.1.2. Market Size of Short Bowel Syndrome by Therapies
8.4.2. Germany
8.4.2.1. Total Market Size of Short Bowel Syndrome
8.4.2.2. Market Size of Short Bowel Syndrome by Therapies
8.4.3. France
8.4.3.1. Total Market Size of Short Bowel Syndrome
8.4.3.2. Market Size of Short Bowel Syndrome by Therapies
8.4.4. Italy
8.4.4.1. Total Market Size of Short Bowel Syndrome
8.4.4.2. Market Size of Short Bowel Syndrome by Therapies
8.4.5. Spain
8.4.5.1. Total Market Size of Short Bowel Syndrome
8.4.5.2. Market Size of Short Bowel Syndrome by Therapies
8.4.6. United Kingdom
8.4.6.1. Total Market Size of Short Bowel Syndrome
8.4.6.2. Market Size of Short Bowel Syndrome by Therapies
8.4.7 Japan
8.4.7.1. Total Market Size of Short Bowel Syndrome
8.4.7.2 Market Size of Short Bowel Syndrome by Therapies
9. Report Methodology
9.1. Sources Used
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Related Reports:
Short Bowel Syndrome – Pipeline Insights, 2020
The Short Bowel Syndrome report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Short Bowel Syndrome across the complete product development cycle, including all clinical and nonclinical stages.
Short Bowel Syndrome – Epidemiology Forecast to 2030
The Short Bowel Syndrome epidemiology covered in the report provides historical as well as forecasted Short Bowel Syndrome epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NEVADA 89107
Country: United States
Website: https://www.delveinsight.com/